Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06744140

Role of MRI Breast in Detection of Ductal Carcinoma in Situ

"This study investigates the role of Magnetic Resonance Imaging (MRI) in detecting Ductal Carcinoma in situ (DCIS) in high-risk breast cancer patients.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Carcinoma in Situ Carcinoma Neoplasms Neoplasms by Histologic Type Neoplasms, Glandular and Epithelial

Age range

30 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

INMOL hospital

Lahore, Punjab Province, Pakistan

About this study

Improved detection rates of DCIS in high-risk patients. Enhanced diagnostic accuracy, reducing false positives and negatives. Ductal Carcinoma in situ (DCIS) is a non-invasive breast cancer where abnormal cells are confined to the milk ducts.

The Breast Imaging Reporting and Data System (BI-RADS) is a standardized scoring system used to classify breast imaging findings. Scores range from 0 (incomplete) to 6 (known biopsy-proven malignancy)."

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • High-risk breast cancer patients with a family history of breast cancer or genetic predispositions (e.g., BRCA mutations).
  • Patients aged 30-65 years.
  • Patients willing to undergo breast MRI screening for DCIS detection.

Exclusion criteria

  • Patients with contraindications to MRI imaging (e.g., pacemakers, claustrophobia).
  • Patients with a history of prior breast surgery or interventions that may interfere with imaging interpretation.

Treatment and study plan

Magnetic Resonance Imaging (MRI)

Diagnostic Test

To Evaluate the breast Magnetic Resonance Imaging (MRI) in detecting Ductal Carcinoma In Situ (DCIS) lesions among high-risk breast cancer patients while keeping the histopathology as a GOLD standard

Primary outcomes

  1. sensitivity & specificity

    Time frame: 12 Months

    sensitivity & specificity of MRI in detecting DCIS

  2. BIRADS scores

    Time frame: 12 Months

    BIRADS scores will be used to evaluate the diagnostic accuracy of MRI in detecting DCIS

Sponsors and collaborators

Lead sponsor

Superior University

Other

Registry information

Important dates

Study start
2024
Primary completion
2024
Study completion
2025
First posted
Dec 20, 2024
Registry last updated
Dec 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.